ABCL vs CRNX
AbCellera Biologics Inc. vs Crinetics Pharmaceuticals, Inc. — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
67
Buy
VS
CRNX
Crinetics Pharmaceuticals, Inc.
69
Buy
| Metric | ABCL | CRNX |
|---|
| AI Score |
67
|
69
|
| Price |
$11.38
|
$84.69
|
| P/E Ratio |
-21.07×
|
-16.77×
|
| ROE |
-15.1%
|
-46.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
99.2%
|
| Debt / Equity |
0.15×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
93.5
|
90.0
|
| Beta |
1.191
|
0.1302
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ABCL versus CRNX.
CRNX leads by 2 points.
CRNX scores 69/100 (Buy) versus ABCL at 67/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 93 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
CRNX Committee View
80% agreement
5 analysts
The primary driver is 3 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 90 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical